Sensirion to start production of SHT21 sensor

Published: 29-Mar-2010
Regulatory

Swiss manufacturer says it is the smallest digital humidity sensor in the world

Sensirion, a Swiss manufacturer of CMOS-based sensor components and systems, is to begin serial production of the SHT21 next month (April).

The SHT21 consists of a newly designed sensor chip encapsulated in a DFN 3-0 package. With this encapsulation the chip is completely over-moulded, except for the humidity sensing area. This reduces the component’s size to 3x3mm with a height of 1.1mm. The company says it also provides protection against condensation and harsh environments, therefore giving outstanding long-term stability.

Typical sensor accuracy is ±2% RH over 20–80% RH and ±0.3 °C over 25–42°C.

A scan path routine enables detailed sensor quality checking, while individual detailed tracking information on the chip can be read out by a simple command. Additionally, the SHT21 is reflow solderable without any degradation of sensor performance. The sensor is provided on tape and reel to facilitate trouble-free handling.

See more

You may also like

Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Read more
Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices

Trending Articles

  1. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  2. Trump warning: drugmakers must expand US manufacturing or face tariffs The president announced a new 100% tariff on branded medicines unless manufacturers are already building US plants
  3. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.
  4. Pfizer strikes landmark deal with US government to lower drug prices The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
  5. EDQM to play key role in strengthening African medicines regulation This initiative marks a significant step forward in global regulatory co-operation and reflects the EDQM’s commitment to promoting access to safe and effective, high-quality medicines worldwide

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Quality control: the central pillar supporting peptide manufacturing

Amid the growing complexity and innovation in the field, this article explores how centralised quality control plays a pivotal role by ensuring both safety and consistency during custom peptide production
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
Regulatory

Pfizer strikes landmark deal with US government to lower drug prices

The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
Regulatory

Trump warning: drugmakers must expand US manufacturing or face tariffs

The president announced a new 100% tariff on branded medicines unless manufacturers are already building US plants
Subscribe now